NEW YORK, June 29, 2017 /PRNewswire/ -- Neurotrope,
Inc. (NASDAQ: NTRP) today announced the acceptance of a late
breaking oral presentation at the Alzheimer's Association
International Conference 2017 (AAIC) being held in London from July 16 -
20, 2017.
The presentation will be given by Dr. Martin R. Farlow, MD, Vice-Chairman for Research
in the Department of Neurology, Indiana
University School of Medicine, Indiana Alzheimer Disease
Center. It will feature results from Neurotrope's recently
completed Phase 2 study of bryostatin - a protein kinase C epsilon
(PKCε) modulator - in the treatment of patients with
moderate-severe to severe AD. The study was designed to
assess the dosing, safety, and preliminary efficacy for 2 different
doses of bryostatin versus placebo.
Details of the presentation are as follows:
Date: Wednesday, 19 July,
2017
Presentation Time: 4:15 PM to
4:30PM
Location: Excel London Auditorium
Session Name: DT-02 Developing Topics: Clinical Trials
Presentation Title: DT-02-01: Effect of Bryostatin-1 on
Cognition and Daily Living Tasks in Moderate to Severe Alzheimer's
disease Preliminary Report of a Phase 2 Study.
"Our understanding of bryostatin, its target PKCε, and the roles
that PKCε plays in synaptogenesis, prevention of neuronal death,
and anti-amyloid, anti-tau activity has emerged from discoveries
that have been made over nearly three decades of research and
development at the National Institutes of Health, Blanchette
Rockefeller Neurosciences Institute at WVU, and at Neurotrope," said Dr. Daniel Alkon, MD, President and Chief Scientific
Officer of Neurotrope. "We, at Neurotrope, are delighted to have
this opportunity to share the molecular basis of our research,
along with the results of our Phase 2 study, with the world leaders
in AD who will be attending the AAIC meeting in London."
About Bryostatin
Bryostatin-1 is the first PKCε modulator to be tested in a
phase 2 clinical study for patients suffering from moderate to
severe AD — a difficult to treat population.
The rationale for researching this novel mechanism in AD results
from in vitro and in vivo models of AD demonstrating that
modulation of PKCε by Bryostatin-1 enhances synaptogenesis and
prevents neuronal death. As synaptic loss is tightly
correlated with cognitive impairment in AD, this attribute of the
molecule made bryostatin an intriguing candidate for additional
investigation in dementia. Furthermore, preclinical studies also
demonstrated bryostatin reduces toxic Aß levels, prevents plaque
formation, inhibits tau phosphorylation, and enhances
cognition. Thus the multimodal effects of this first PKCε
modulator offer an attractive new mechanism to study in AD with the
ultimate goal to slow or prevent the progression of
disease.
About Neurotrope
Neurotrope is at the forefront of developing a new approach to
combatting AD and other neurodegenerative diseases. The
Company's world-class science offers the potential to realize a
paradigm shift to overcome one of today's most challenging clinical
problems — finding a way to slow or even prevent the progression of
AD.
In addition to the Company's Phase 2 trial of bryostatin-1 in
moderate to severe AD, Neurotrope has also conducted preclinical
studies of bryostatin as a potential treatment for Fragile X
Syndrome, Niemann-Pick Type C disease and Rett Syndrome—three rare
genetic diseases for which only symptomatic treatments are
currently available. The FDA has granted Orphan Drug Designation to
Neurotrope for Bryostatin-1 as a treatment for Fragile X
Syndrome. Bryostatin-1 has already undergone testing in more
than 1,500 people in cancer studies, thus creating a large safety
data base that will further inform clinical trial designs in
AD.
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. These forward-looking statements include statements
regarding the Phase 2 study and further studies, and continued
development of use of Bryostatin-1 for Alzheimer's dementia and
other cognitive diseases. Such forward-looking statements are
subject to risks and uncertainties and other influences, many of
which the Company has no control over. These statements are subject
to the risk that further analyses of the Phase 2 data may lead to
different interpretations of the data than the analyses conducted
to date and/or may identify important implications of the Phase 2
data that are not reflected in these statements. Clinical
trial data are subject to differing interpretations, and regulatory
agencies, medical and scientific experts and others may not share
the Company's views of the Phase 2 data. There can be no
assurance that the clinical program for Bryostatin-1 will be
successful in demonstrating safety and/or efficacy that we will not
encounter problems or delays in clinical development, or that
Bryostatin-1 will ever receive regulatory approval or be
successfully commercialized. Actual results and the timing of
certain events and circumstances may differ materially from those
described by the forward-looking statements as a result of these
risks and uncertainties. Additional factors that may influence or
cause actual results to differ materially from expected or desired
results may include, without limitation, the Company's inability to
obtain adequate financing, the significant length of time
associated with drug development and related insufficient cash
flows and resulting illiquidity, the Company's patent portfolio,
the Company's inability to expand the Company's business,
significant government regulation of pharmaceuticals and the
healthcare industry, lack of product diversification, availability
of the Company's raw materials, existing or increased
competition, stock volatility and illiquidity, and the
Company's failure to implement the Company's business plans or
strategies. These and other factors are identified and described in
more detail in the Company's filings with the SEC, including the
Company's Annual Report on Form 10-K for the year ended
December 31, 2016 and on Form 10-Q
for the quarter ending March 31,
2017. The Company does not undertake to update these
forward-looking statements.
Please visit www.neurotropebioscience.com for further
information.
Contact information:
Investors
Jeffrey Benison, Director of Corporate Communications
Neurotrope Bioscience, Inc.
973.242.0005 Ext. 101
jbenison@neurotropebioscience.com
Media
James Heins
Senior Vice President
ICR Healthcare
203.856.2121
james.heins@icrinc.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/neurotrope-to-present-bryostatin-phase-2-data-in-an-oral-presentation-at-aaic-2017-meeting-300481656.html
SOURCE Neurotrope, Inc.